Corvus Pharms Q3 net loss $10.2M, cash $65.7M; soquelitinib trials advancing

Corvus Pharmaceuticals, Inc.

2025-Q3 EPS reported -$0.38 vs consensus -$0.14 ▼ miss (-179.2%)

Net loss of $10.2M for Q3 2025, improved from $40.2M loss in Q3 2024 which included $32.8M non-cash warrant liability loss.
Cash, equivalents & marketable securities $65.7M as of Sept 30, 2025, up from $52.0M at Dec 31, 2024; funding expected into Q4 2026.
Completed enrollment in soquelitinib atopic dermatitis Phase 1 extension cohort 4 (200 mg BID, 8 weeks); data expected January 2026.
On track to initiate soquelitinib atopic dermatitis Phase 2 trial in early Q1 2026, targeting ~200 patients.
Phase 3 registrational trial of soquelitinib in relapsed/refractory PTCL enrolling; final Phase 1/1b results to be presented at ASH December 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.